Add
ALXN to Portfolio
Set Alert
Email to a
Friend
| |||
|
|
Quotes & Info
|
| ALXN > SEC Filings for ALXN > Form 8-K on 14-Feb-2013 | All Recent SEC Filings |
14-Feb-2013
Results of Operations and Financial Condition, Financial Statements a
On February 14, 2013, Alexion Pharmaceuticals, Inc. issued a press release
relating to its results of operations and financial conditions for the quarter
and year ended December 31, 2012. A copy of the press release is furnished as
Exhibit 99.1 to this Form 8-K.
The attached press release contains both U.S. Generally Accepted Accounting
Principles, or GAAP, and non-GAAP financial measures. The non-GAAP financial
measures exclude share-based compensation, costs associated with acquisitions,
taxes related to acquisition structuring, intangible asset impairments and taxes
not payable in cash. Reconciliations between non-GAAP and GAAP financial
measures are included in the press release set forth as Exhibit 99.1 furnished
to this Form 8-K. Alexion's management utilizes non-GAAP financial information
to provide a useful measure of comparative operating performance of Alexion. The
non-GAAP financial measures are supplemental to and not a substitute for,
measures of financial performance prepared in accordance with GAAP.
(d) Exhibits
99.1 Press Release issued by Alexion Pharmaceuticals, Inc. on February 14, 2013 relating to its results of operations and financial conditions for the quarter and year ended December 31, 2012.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: February 14, 2013 ALEXION PHARMACEUTICALS, INC.
By: /s/ Michael V. Greco Name: Michael V. Greco Title: Associate General Counsel and Corporate Secretary
|
|